Q32 Bio Inc (QTTB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $260.64M
Last updated: Nov 17, 2026 at 11:06 AM ET
Q32 Bio Inc (QTTB) Financials: Revenue, Profit and Cash Flow
Q32 Bio reported revenue of $53.74M for the fiscal year ended Dec 31, 2025. That year, net income was $29.82M with a net margin of 55.5%, operating cash flow was -$33.54M and free cash flow was -$33.54M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$8.92M.
Revenue and Margins
The operating margin was 31.5% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $5.32M, a compound annual rate of 39.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $53.74M | N/A | 100.0% | 31.5% | 55.5% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | -$6.65M | -307.3% | N/A | N/A | N/A |
| Dec 2022 | $3.21M | -90.6% | 100.0% | -4154.6% | -156.0% |
| Dec 2021 | $33.97M | +1157.3% | 100.0% | -282.4% | -281.9% |
| Dec 2020 | $2.70M | +62.2% | 100.0% | -4821.0% | -4762.9% |
| Dec 2019 | $1.67M | -68.7% | 100.0% | -6599.2% | -6237.5% |
| Dec 2018 | $5.32M | N/A | 100.0% | -1126.0% | -1044.3% |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.74M | $0 | -$6.65M | $3.21M | $33.97M | $2.70M | $1.67M | $5.32M | $0 | N/A |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $239.80K |
| Gross profit | $53.74M | $0 | -$6.65M | $3.21M | $33.97M | $2.70M | $1.67M | $5.32M | $0 | -$239.80K |
| Research and development | $19.16M | $48.14M | $31.73M | $98.35M | $93.08M | $100.39M | $89.40M | $47.95M | $21.38M | $5.69M |
| Operating income | $16.90M | -$66.10M | -$48.26M | -$133.28M | -$95.95M | -$130.26M | -$109.94M | -$59.93M | -$29.66M | -$10.00M |
| Net income | $29.82M | -$47.73M | -$53.74M | -$5.00M | -$95.76M | -$128.69M | -$103.92M | -$55.58M | -$29.99M | -$8.05M |
| EBITDA | $30.39M | -$45.63M | N/A | -$2.69M | -$88.49M | -$122.50M | -$103.63M | N/A | N/A | -$7.81M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $53.74M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$14.66M |
| Gross profit | $0 | $0 | $0 | $53.74M | $0 | $0 | $0 | -$120.00K | $0 | $0 | $0 | -$14.66M |
| Operating income | -$10.66M | -$9.12M | -$7.72M | $45.88M | -$7.58M | -$9.17M | -$12.23M | -$14.53M | -$18.81M | -$17.92M | -$14.84M | -$25.81M |
| Net income | -$8.92M | -$8.95M | -$7.61M | $57.73M | -$7.39M | -$9.49M | -$11.03M | -$14.19M | -$17.59M | -$16.98M | $1.03M | -$27.07M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $9.71M by $38.59M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $61.78M | $92.33M | $47.06M | $228.47M | $211.72M | $263.74M | $310.57M | $259.09M | $137.53M | $14.22M |
| Current assets | $55.05M | $81.88M | $28.72M | $181.01M | $191.91M | $219.56M | $266.58M | $221.69M | $131.60M | $11.99M |
| Cash and equivalents | $48.30M | $77.97M | $25.62M | $33.99M | $108.38M | $217.43M | $53.77M | $38.22M | $51.58M | $11.39M |
| Total liabilities | $19.76M | $86.66M | $118.53M | $50.49M | $42.07M | $67.74M | $52.06M | $62.74M | $39.22M | $6.72M |
| Short-term debt | $6.24M | $3.10M | $878.00K | $32.87M | $246.00K | $2.50M | N/A | N/A | N/A | N/A |
| Long-term debt | $3.47M | $9.56M | $43.18M | $5.07M | $4.97M | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $42.01M | $5.67M | -$182.92M | $177.98M | $169.65M | $196.00M | $258.51M | $196.35M | -$39.45M | $7.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $297.20M | $115.87M | $63.67M | $61.78M | $57.78M | $66.12M | $79.07M | $92.33M | $104.54M | $124.21M | $152.33M | $47.06M |
| Total liabilities | $9.53M | $9.96M | $17.36M | $19.76M | $76.23M | $78.35M | $83.08M | $86.66M | $86.25M | $90.70M | $103.56M | $229.98M |
| Cash and equivalents | $289.59M | $106.27M | $50.75M | $48.30M | $49.04M | $54.83M | $65.48M | $77.97M | $89.08M | $97.66M | $115.51M | $25.62M |
| Shareholder equity | $287.67M | $105.91M | $46.31M | $42.01M | -$18.45M | -$12.23M | -$4.01M | $5.67M | $18.30M | $33.51M | $48.77M | -$182.92M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.54M | -$67.72M | -$18.68M | -$113.66M | -$109.75M | -$94.33M | -$91.36M | -$42.56M | $6.48M | -$8.48M |
| Capital expenditures | $0 | $75.00K | $5.00K | $1.28M | $2.40M | $3.73M | $21.83M | $24.94M | $1.96M | $1.99M |
| Free cash flow | -$33.54M | -$67.79M | -$18.68M | -$114.95M | -$112.15M | -$98.06M | -$113.19M | -$67.50M | $4.52M | -$10.47M |
| Investing cash flow | $7.00M | $19.93M | -$5.00K | $36.72M | -$50.79M | $204.90M | -$51.80M | -$121.79M | -$81.53M | -$2.27M |
| Financing cash flow | -$3.13M | $95.14M | $406.00K | $596.00K | $52.17M | $53.09M | $158.21M | $150.99M | $115.23M | $378.31K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.42M | -$3.08M | -$6.34M | -$6.18M | -$4.23M | -$10.65M | -$12.48M | -$11.43M | -$19.52M | -$22.21M | -$14.55M | -$10.71M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $2.00K | $0 | $2.00K | $58.00K | $15.00K | $0 | $0 |
| Free cash flow | N/A | N/A | -$6.34M | -$6.18M | -$4.23M | -$10.65M | -$12.48M | -$11.43M | -$19.58M | -$22.23M | -$14.55M | -$10.71M |
Frequently Asked Questions About QTTB
What is Q32 Bio's annual revenue?
Q32 Bio reported revenue of $53.74M for the fiscal year ended Dec 31, 2025.
Is Q32 Bio profitable?
Yes. Q32 Bio reported net income of $29.82M for the fiscal year ended Dec 31, 2025, with a net margin of 55.5%.
How much free cash flow does QTTB generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$33.54M minus capital expenditures of $0 produced free cash flow of -$33.54M.
How much debt does Q32 Bio have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $3.47M, short-term debt of $6.24M and cash and equivalents of $48.30M.
What is QTTB's profit margin?
For the fiscal year ended Dec 31, 2025, Q32 Bio reported gross margin of 100.0%, operating margin of 31.5% and net margin of 55.5%.
QTTB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors